GlobeNewswire PharmaOriginal article
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
Data ReadoutpositiveVabysmoPositive
AI Analysis
Summary
Roche presented VOYAGER study data showing Vabysmo (faricimab) demonstrates real-world effectiveness and safety across nAMD, DME, and RVO indications, with results consistent with Phase III trial outcomes.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
VOYAGER study demonstrates real-world effectiveness of Vabysmo in nAMD, DME, and RVO with vision gains and anatomical improvements consistent with Phase III trial results
Importance:6/10
Sentiment:
0.70
ophthalmologyreal-world evidenceVOYAGER studyEURETINA presentationretinal diseases
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 1, 2026 6:00 AM